16,124
Participants
Start Date
October 30, 2018
Primary Completion Date
July 31, 2026
Study Completion Date
December 31, 2049
Inclisiran
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Placebo
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
TIMI Study Group, Boston
CTSU, University of Oxford, Oxford
Collaborators (1)
The TIMI Study Group
OTHER
Novartis Pharmaceuticals
INDUSTRY
University of Oxford
OTHER